SUV_max during 18FDG-PET scanning in small cell lung cancer: Similar information as in non-small cell lung cancer?

详细信息	查看全文 | 推荐本文 |

• 作者：C. van der Leest^a ; ^b ; E.F. Smit^c ; J. Baas^d ; R.J. Versteijlen^e ; N. van Walree^a ; H.C. Hoogsteden^b ; J.G.J.V. Aerts^a ; ^b ; ^{jaerts@amphia.nl}
• 关键词：18FDG-PET ; Small cell lung cancer ; SUVmax ; Overall survival ; Progression free survival ; Stage IV disease
• 刊名：Lung Cancer
• 出版年：2012
• 期刊代码：187_01695002
• 类别：med
• 出版时间：April, 2012
• 卷：76
• 期：1
• 页码：67-71
• 文件大小：314 K

摘要

In patients with non-small cell lung carcinoma (NSCLC) fluorine-18 fluorodeoxyglucose positron emission tomography (18FDG-PET)-scanning is shown to be of prognostic value. Small cell lung cancer (SCLC) is an aggressive tumor with poor prognosis. Limited results on the prognostic and predictive value of the maximum standard uptake values (SUV_max) obtained during 18FDG-PET scanning in SCLC are available.

An observational study in 75 chemonaive patients diagnosed with SCLC who underwent a 18FDG-PET scan was performed. SUV_max values of the primary tumor were related to the overall survival (OS) and the progression free survival (PFS).

Significant lower SUV_max values of the primary tumor were observed in patients with stage I-III disease compared to stage IV disease. SUV_max did not discriminate for either OS or PFS in the whole group of patients. In patients with stage IV disease and treatment with chemotherapy, OS and PFS were significantly higher in patients with a high SUV_max. (p-value 0.005 and 0.002 respectively) compared to patients with a low SUV_max value.

In patients with SCLC metabolic activity determined using 18FDG-PET (SUV_max) differed between stage I-III and stage IV diseases. Compared to NSCLC, the relationship between SUV_max and prognosis seems more complex.